Jianmin Fang

1239 Siping Road
Shanghai, 200092, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 79 publications

Telitacicept for IgA Nephropathy - Interim Analysis of a Phase 3 Trial.

Telitacicept for IgA Nephropathy - Interim Analysis of a Phase 3 Trial.

Journal: The New England journal of medicine

Published: May 13, 2026

Conformational epitope engagement by anti-MSLN ADC RC88 confers resistance to soluble mesothelin.

Conformational epitope engagement by anti-MSLN ADC RC88 confers resistance to soluble mesothelin.

Journal: Antibody therapeutics

Published: March 06, 2026

Disitamab Vedotin plus Toripalimab in HER2-Expressing Advanced Urothelial Cancer.

Disitamab Vedotin plus Toripalimab in HER2-Expressing Advanced Urothelial Cancer.

Journal: The New England journal of medicine

Published: October 22, 2025

Peroxisome Functional Inhibition Alleviates TMJOA Cartilage Degradation.

Peroxisome Functional Inhibition Alleviates TMJOA Cartilage Degradation.

Journal: Journal of dental research

Published: October 18, 2025

A Phase 3 Trial of Telitacicept for Systemic Lupus Erythematosus.

A Phase 3 Trial of Telitacicept for Systemic Lupus Erythematosus.

Journal: The New England journal of medicine

Published: October 15, 2025

TROP2 antibody-drug conjugate: unique epitope engagement drives differentiated efficacy.

TROP2 antibody-drug conjugate: unique epitope engagement drives differentiated efficacy.

Journal: Antibody therapeutics

Published: July 23, 2025

Solving the light chain mismatch of IgG-like bispecific antibody by utilizing 2A peptide based FaBody platform.

Solving the light chain mismatch of IgG-like bispecific antibody by utilizing 2A peptide based FaBody platform.

Journal: Biotechnology reports (Amsterdam, Netherlands)

Published: April 07, 2025

Corrigendum to "Mesencephalic astrocyte-derived neurotrophic factor alleviated 6-OHDA-induced cell damage via ROS-AMPK/mTOR mediated autophagic inhibition" [Exp. Gerontol. Volume 89 (2017), 45-56].

Corrigendum to "Mesencephalic astrocyte-derived neurotrophic factor alleviated 6-OHDA-induced cell damage via ROS-AMPK/mTOR mediated autophagic inhibition" [Exp. Gerontol. Volume 89 (2017), 45-56].

Journal: Experimental gerontology

Published: March 27, 2025

Therapeutically targeting endometrial cancer in preclinical models by ICAM1 antibody-drug conjugates.

Therapeutically targeting endometrial cancer in preclinical models by ICAM1 antibody-drug conjugates.

Journal: Gynecologic oncology

Published: January 10, 2025

Intravesical Disitamab Vedotin (RC48) for HER2-Expressing High-Risk Non-Muscle-Invasive Bladder Cancer: A Single-Arm, Dose-Escalation Phase I Trial Study.

Intravesical Disitamab Vedotin (RC48) for HER2-Expressing High-Risk Non-Muscle-Invasive Bladder Cancer: A Single-Arm, Dose-Escalation Phase I Trial Study.

Journal: MedComm

Published: December 21, 2024

Efficacy and safety of DV in HER2-negative and HER2-low locally advanced or metastatic urothelial carcinoma: Results of a phase 2 study.

Efficacy and safety of DV in HER2-negative and HER2-low locally advanced or metastatic urothelial carcinoma: Results of a phase 2 study.

Journal: Med (New York, N.Y.)

Published: September 02, 2024

Perivascular Niche-Resident Alveolar Macrophages Promote Interstitial Pneumonitis Related to Trastuzumab Deruxtecan Treatment.

Perivascular Niche-Resident Alveolar Macrophages Promote Interstitial Pneumonitis Related to Trastuzumab Deruxtecan Treatment.

Journal: Cancer research

Published: June 20, 2024

Showing 1-12 of 79

Last Updated: 09/26/2026